Short-term dietary salt supplementation blunts telmisartan induced increases in plasma renin activity in hypertensive patients with type 2 diabetes mellitus

Current guidelines recommend low dietary salt intake in patients with diabetes to reduce blood pressure. However, low salt intake has been associated with higher mortality rates in people with diabetes. Our aim is to examine the effect of angiotensin II receptor blocker (ARB), telmisartan, with and without dietary sodium chloride (NaCl) supplementation, on blood pressure (mean arterial pressure, MAP), plasma renin activity (PRA), serum aldosterone level and estimated glomerular filtration rate (eGFR) in hypertensive patients with type 2 diabetes. In a randomised, double blind, controlled study (RCT), 28 patients with type 2 diabetes, treated with telmisartan (40mg daily), received two weeks of placebo or NaCl capsules (100mmol/24h). Following a six-week washout, the protocol was repeated in reverse. Twenty-four hour urinary sodium excretion (24hUNa), ambulatory blood pressure monitoring and blood tests were performed before and after each study phase. The telmisartan associated increase in PRA was blunted by approximately 50% during salt supplementation compared with placebo; median PRA was 2.3 ug/l/hr with placebo vs 1.7ug/l/hr with salt (p
Source: Clinical Science - Category: Biomedical Science Authors: Source Type: research

Related Links:

Authors: Andreeva-Gateva PA, Mihaleva ID, Dimova II Abstract Diabetes mellitus and cardiovascular diseases are part of the metabolic syndrome and share similar risk factors, including obesity, arterial hypertension, and dyslipidemia. Atherosclerosis and insulin resistance contribute to the development of the diseases, and subclinical inflammation is observed in both conditions. There are many proofs about the connection between epigenetic factors and different diseases, including diabetes and cardiovascular diseases. Interestingly, recent studies show that at least some anti-diabetic drugs, as well as blockers of t...
Source: Postgraduate Medicine - Category: Internal Medicine Tags: Postgrad Med Source Type: research
Publication date: 15 October 2019Source: Cell Reports, Volume 29, Issue 3Author(s): Yongxu Zhao, Zhuanghui Feng, Qiurong DingSummaryThis Matters Arising Response paper addresses the Hoch et al. (2019) Matters Arising paper published concurrently in this issue of Cell Reports. The genetic study in humans revealed a strong association of DNA variants in the SLC16A11 coding region with type 2 diabetes mellitus (T2DM). However, how these T2D variants affect the function of SLC16A11 remains controversial. In Zhao et al. (2019), with studies using genetic knockout mouse models and in vivo gene reconstitution exper...
Source: Cell Reports - Category: Cytology Source Type: research
Despite the increasing burden of diabetes in Uganda, little is known about the quality of type 2 diabetes mellitus (T2DM) care especially in rural areas. Poor quality of care is a serious limitation to the con...
Source: BMC Health Services Research - Category: General Medicine Authors: Tags: Research article Source Type: research
This study aims to evaluate firstly the experiences, barriers and facilitators to app usage a...
Source: Diabetology and Metabolic Syndrome - Category: Endocrinology Authors: Tags: Research Source Type: research
AbstractBackgroundOur previous pilot study using patients with type 2 diabetes mellitus in one medical clinic showed an association of urinary albumin excretion, a marker of generalized vascular dysfunction and kidney damage, with periodontitis. The purpose of this study was to confirm the association by increasing the number of patients and medical clinics.MethodsParticipants were 2302 patients (59.9% males, aged 29 –93 years) with type 2 diabetes mellitus from 25 medical clinics. Their medical records and information about socioeconomic status and health behavior were collected. Periodontal status was assessed...
Source: Diabetology International - Category: Endocrinology Source Type: research
Thyroid dysfunction is a risk factor for cardiovascular disease. Whether thyroid function within the normal range is a risk factor for cardiovascular disease remains uncertain. The aim of this study is to evaluate whether plasma thyroid-stimulating hormone (TSH) levels in the normal range are a risk factor for cardiovascular disease and mortality in participants with type 2 diabetes mellitus with high cardiovascular risk.
Source: Diabetes Research and Clinical Practice - Category: Endocrinology Authors: Source Type: research
In conclusion, Chinese postmenopausal women with T2DM had a similar risk of incident VFs, but a significantly higher risk of incident non-VF, compared to women without DM. Higher BMI did not modify the effect of T2DM on risk of VFs, but it increased the association be tween T2DM and risk of non-VFs. LS BMDT-score was similarly and negatively associated with VF risk in T2DM and non-DM women and appear to be useful for clinical evaluation of VF risk.
Source: Calcified Tissue International - Category: Orthopaedics Source Type: research
Source: Critical Reviews in Food Science and Nutrition - Category: Nutrition Authors: Source Type: research
Gestational diabetes (GDM) is a known risk factor for type 2 diabetes mellitus (T2DM), and women with a history of GDM have a 7-fold increased risk of developing the disease. Achieving a healthy weight post-de...
Source: BMC Public Health - Category: Consumer Health News Authors: Tags: Study protocol Source Type: research
Abstract The antidiabetic effect of liraglutide in patients with type 2 diabetes mellitus has been explored in several trials. We performed this meta-analysis determining the effects of liraglutide on blood pressure in these patients. Three electronic databases (Pubmed, Web of Science, and Cochrane Central) were searched for all published articles evaluating the effects of liraglutide on blood pressure in subjects with type 2 diabetes mellitus. Total 968 patients were included in 10 randomized, double-blind, placebo-controlled trials with a follow-up of 16 ± 9 weeks. Liraglutide 1.8 mg/day reduced systolic ...
Source: Clinical and Experimental Hypertension - Category: Cardiology Authors: Tags: Clin Exp Hypertens Source Type: research
More News: Biomedical Science | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Nutrition | Science | Sodium Chloride | Study